Abstract
Urticaria is a skin disease that is clinically manifested by redness and itching of the skin, sometimes with swelling. Urticaria is most often caused by an allergic reaction to household or pollen allergens, contact allergy, infection, autoimmune diseases, oncology, etc. According to various sources, we cannot determine the cause of the disease in 20-30% of patients.
Choosing a drug for treatment is always significant in case of exacerbation, most commonly recommended for treating patients with urticaria are second-generation H1 receptor blockers. If necessary, the dosage may be increased in several times. In patients who cannot achieve symptom control with H1 receptor blockers alone, systemic glucocorticoids are used in short courses (5-7 days), omalizumab, and anti-leukotriene drugs. Using the urticaria activity test (UAS7), we were able to compare the efficacy of therapeutic doses of rupatadine, bilastine, and fexofenadine in the first seven days of treatment.
References
2. Salman A, Porras NM, Gimenez-Arnau AM. Acute and Chronic Urticaria Diagnosis and Management Taking into Account Their Differences. Allergy. 2023;10;130-147.
3. Ansotegui IJ, Bernstein JA, Canonica GW et al. Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride. Allergy Asthma Clin Immunol. 2022;18(1):41.
4. Sánchez J, Sánchez A, Munera M. Presence of IgE Autoantibodies Against Eosinophil Peroxidase and Eosinophil Cationic Protein in Severe Chronic Spontaneous Urticaria and Atopic Dermatitis. Allergy Asthma Immunol Res. 2021;13(5):746-761.
5. Karstarli Bakay OS, Demir B, Cicek D. et al. In chronic spontaneous urticaria, IgE and C-reactive protein are linked to distinct microRNAs and interleukin-31. Clin Transl Allergy. 2023;13(8):e12290.
6. Navarro-Triviño FJ. Pruritus in Dermatology: Part 2 — Diseases and Their Treatment Actas Dermosifiliogr. 2023;114(7):613-626.
7. Javaud N, Soria A, Maignan M et al. Glucocorticoids for acute urticaria: study protocol for a double-blind non-inferiority randomised controlled trial. BMJ Open. 2019; 9(8):e027431.
8. de Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10(1):24.
9. Alkeraye S, AlRuhaimi DK. The Addition of Montelukast for the Treatment of Chronic Idiopathic Urticaria. Cureus. 2021;13(7):e16137.
10. Zuberbier T, Abdul Latiff AH, Abuzakouk M et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria Allergy. 2022 Mar;77(3):734-766.
11. Terhorst-Molawi D, Fox L, Siebenhaar F, Metz M, Maurer M. Stepping Down Treatment in Chronic Spontaneous Urticaria: What We Know and What We Don’t Know. Am J Clin Dermatol. 2023;24(3):397-404.